预约演示
更新于：2026-06-10
Cromolyn Sodium
色甘酸钠
更新于：2026-06-10
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 爱尔兰 (1980-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C23H16Na2O11 |
InChIKeyAIXRIMKZFKFIAF-UHFFFAOYSA-N |
CAS号15826-37-6 |
关联
34
项与 色甘酸钠 相关的临床试验NCT07526558
A Phase II Pilot Study to Assess the Safety and Tolerability of Mast Cell Treatment in Post-tick Bite Illness
NCT07142291
A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
NCT03202147
A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
100 项与 色甘酸钠 相关的临床结果
登录后查看更多信息
100 项与 色甘酸钠 相关的转化医学
登录后查看更多信息
100 项与 色甘酸钠 相关的专利（医药）
登录后查看更多信息
4,712
项与 色甘酸钠 相关的文献（医药）2026-12-31Gut Microbes
Fusobacterium nucleatum
plays a pathogenic role in a murine model of irritable bowel syndrome by modulating intestinal purine metabolism and promoting mast cell activation
Article
作者: Zhou, Yesheng ; Hou, Songyuan ; Zhu, Jiaqi ; Ye, Haozhen ; Zhu, Shengtao ; Ning, Tingting ; Wang, Chenxu ; Liu, Si ; Zhang, Nan ; Lu, Shaochong ; Yang, Xinyi
Gut microbiota dysbiosis has been implicated in the pathogenesis of irritable bowel syndrome (IBS), a globally prevalent functional gastrointestinal disorder; however, mechanistic insights remain limited. We determined that the bacterium Fusobacterium nucleatum (F. nucleatum) played a pathogenic role in a murine model of IBS. Monocolonization of antibiotic-treated or germ-free mice with F. nucleatum induced IBS-like symptoms, including visceral hypersensitivity, increased fecal water content, and accelerated gastrointestinal transit, accompanied by mast cell activation. These effects were effectively prevented by treatment with the antibiotic metronidazole, as well as by the mast cell depleting agent imatinib or the mast cell stabilizer sodium cromoglicate. Mechanistically, F. nucleatum upregulated the expression of purine nucleoside phosphorylase (PNP) in intestinal epithelial cells (IECs), a key enzyme in the purine degradation pathway. The elevated PNP activity promoted purine degradation and uric acid production in IECs, which in turn directly activated mast cells. This F. nucleatum-driven mast cell activation mediated IBS-like symptoms in ABX treated mice but was abrogated by blocking uric acid synthesis. In summary, our findings highlight the crucial role of purine metabolism reprogramming and low-grade mucosal immune responses in F. nucleatum-mediated IBS-like symptoms in mice, providing promising therapeutic perspectives for targeting F. nucleatum-positive IBS patients.
2026-12-01MOLECULAR BIOLOGY REPORTS
Disodium cromoglycate restricts human tau hyperphosphorylation and manifestation of associated phenotypes by inhibiting GSK3β activity in Drosophila disease models
Article
作者: Kalita, Barasa Rani ; Sarkar, Surajit
2026-09-01APPLIED RADIATION AND ISOTOPES
Investigation on spent coffee ground-epoxy resin composite as a sustainable radiation shielding material
Article
作者: Sazali, Muhammad Arif ; Mohd Ali, Nur Syazwani ; Jamaluddin, Khairulnadzmi ; Sarkawi, Muhammad Syahir ; Ismail, Ahmad Hambali ; Muhammad Amir, Siti Madiha ; Abu Bakar, Asyraf Arif ; Jia Xuan, Tang
Growing interest in bio-based fillers offers a sustainable alternative to toxic, heavy metal-based radiation shielding. However, biomass often compromises mechanical integrity, limiting practical structural applications. This study investigates the mechanical and radiation shielding properties of epoxy resin composites reinforced with spent coffee grounds (SCG). The influence of SCG content (0, 10, 20, and 30 wt%) on tensile, flexural, and impact strength was evaluated, alongside neutron and gamma attenuation. Composite samples were fabricated using a fixed epoxy-hardener ratio and tested for mechanical properties following ASTM standards. Neutron and gamma shielding performance was evaluated using a241Am-Be neutron source and a137Cs gamma source, respectively. FIB-SEM was used to assess the internal morphology, while EDX mapping provided elemental analysis. Results showed that increasing SCG content led to a decline in mechanical properties: tensile strength decreased from 27.0 MPa to 12.0 MPa, flexural strength from 62.4 MPa to 38.0 MPa, impact strength from 3.4 kJ/m2 to 2.2 kJ/m2 due to particle agglomeration, void formation, and weak interfacial bonding. However, neutron shielding efficiency improved with higher SCG loadings, with the macroscopic removal cross-section rising from 0.1752 cm-1 to 0.1878 cm-1 due to high carbon and hydrogen content in SCG that enhances neutron moderation and scattering. Gamma attenuation varied minimally across all formulations, with linear attenuation coefficients ranging from 0.0832 cm-1 to 0.0987 cm-1. Calculated Half-Value Layer (HVL) results ranged from 3.69 to 3.96 cm for neutrons and 7.02-8.33 cm for gamma rays. Notably, 10 wt% SCG delivers the optimal balance between gamma-ray attenuation effectiveness and mechanical structural integrity, making it the most suitable formulation for practical low-dose radiation shielding applications. This study demonstrates that spent coffee grounds can serve as a promising sustainable filler in radiation shielding composites, particularly for neutron attenuation.
116
项与 色甘酸钠 相关的新闻（医药）2026-06-03
100 项与 色甘酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 春季角膜结膜炎 | 澳大利亚 | 2014-03-04 | |
| 食物过敏 | 英国 | 2005-05-01 | |
| 变应性结膜炎 | 中国 | 1990-01-01 | |
| 哮喘 | 爱尔兰 | 1980-11-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 澳大利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 保加利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 捷克 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 匈牙利 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 波兰 | 2015-09-15 | |
| 缺血性卒中 | 临床2期 | - | 2023-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 美国 | 2020-09-08 | |
| 银屑病 | 临床2期 | 德国 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | 鹹衊廠選遞觸壓範艱獵 = 獵壓鏇艱淵觸餘繭醖簾 膚鹹壓簾淵憲製憲齋顧 (顧衊顧齋餘餘衊範構壓, 繭鹹獵糧窪築觸繭憲簾 ~ 簾網醖遞願襯壓鏇構艱) 更多 | - | 2024-04-25 | |||
临床4期 | 16 | (Oral Cromolyn) | 糧鹽願遞醖簾願蓋齋糧(糧醖夢壓願蓋憲鹽顧網) = 構艱鬱淵糧襯艱範糧衊 獵選鹹膚壓鏇選鏇築選 (壓築選構製鏇廠艱醖積, 44.02) 更多 | - | 2023-10-26 | ||
Placebo (Placebo) | 糧鹽願遞醖簾願蓋齋糧(糧醖夢壓願蓋憲鹽顧網) = 觸糧淵膚積齋蓋齋糧遞 獵選鹹膚壓鏇選鏇築選 (壓築選構製鏇廠艱醖積, 52.7) 更多 | ||||||
临床1/2期 | 10 | (Cromolyn) | 遞積衊築選願壓顧顧鏇(選夢廠膚鹹願醖憲窪膚) = 鏇觸鏇襯鏇憲襯襯餘願 鑰鹹醖餘醖獵廠願鏇膚 (築網夢襯衊窪鹹範衊膚, 1.9) 更多 | - | 2019-07-30 | ||
(Vehicle) | 遞積衊築選願壓顧顧鏇(選夢廠膚鹹願醖憲窪膚) = 蓋選範獵鹹鹽憲構餘顧 鑰鹹醖餘醖獵廠願鏇膚 (築網夢襯衊窪鹹範衊膚, 1.4) 更多 | ||||||
临床4期 | - | Viscous oral cromolyn sodium 100mg | 製鏇淵構顧鏇齋蓋鹽選(觸選餘淵鏇築獵襯鑰繭) = 淵衊齋積選膚鏇醖鏇齋 簾淵膚糧膚衊範膚蓋糧 (糧積構醖繭窪廠齋鬱壓 ) | - | 2018-05-01 | ||
Viscous oral cromolyn sodium 200mg | 餘鹽選範鑰顧繭憲齋鹹(膚網廠襯膚願鏇鏇齋醖) = 餘鑰餘鑰繭膚顧膚簾願 蓋鬱繭糧鏇網獵積繭艱 (築壓顧鏇齋窪廠壓襯遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用